Stockreport

Viridian's REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly [Seeking Alpha]

Viridian Therapeutics, Inc.  (VRDN) 
PDF Elegrobart met its primary endpoint in proptosis reduction and showed strong diplopia resolution in Q4W dosing, but secondary endpoints and dosing consistency were mixe [Read more]